Celyad SA (CYAD) - Total Liabilities

Latest as of June 2025: €8.80 Million EUR ≈ $10.29 Million USD

Based on the latest financial reports, Celyad SA (CYAD) has total liabilities worth €8.80 Million EUR (≈ $10.29 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Celyad SA to see how much of total assets are deployed in long-term investments.

Celyad SA - Total Liabilities Trend (2010–2024)

This chart illustrates how Celyad SA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Celyad SA's balance sheet.

Celyad SA Competitors by Total Liabilities

The table below lists competitors of Celyad SA ranked by their total liabilities.

Company Country Total Liabilities
Crown Point Energy Inc
V:CWV
Canada CA$211.06 Million
Locate Technologies Ltd
AU:LOC
Australia AU$5.58 Million
Soc Franc Casinos
PA:SFCA
France €9.21 Million
Ignite Ltd
AU:IGN
Australia AU$4.89 Million
BAIYU Holdings Inc.
NASDAQ:BYU
USA $80.25 Million
Rma Global Ltd
AU:RMY
Australia AU$10.41 Million
WAG Payment Solutions PLC
LSE:WPS
UK GBX923.77 Million
Wolfden Resources Corporation
V:WLF
Canada CA$827.13K

Liability Composition Analysis (2010–2024)

This chart breaks down Celyad SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Celyad SA balance sheet quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.66 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -2.84 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.54 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Celyad SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Celyad SA (2010–2024)

The table below shows the annual total liabilities of Celyad SA from 2010 to 2024.

Year Total Liabilities Change
2024-12-31 €26.05 Million
≈ $30.45 Million
+161.05%
2023-12-31 €9.98 Million
≈ $11.67 Million
-35.20%
2022-12-31 €15.40 Million
≈ $18.00 Million
-57.58%
2021-12-31 €36.30 Million
≈ $42.44 Million
+3.46%
2020-12-31 €35.09 Million
≈ $41.02 Million
-20.64%
2019-12-31 €44.22 Million
≈ $51.69 Million
+14.23%
2018-12-31 €38.71 Million
≈ $45.26 Million
+28.64%
2017-12-31 €30.09 Million
≈ $35.18 Million
-37.21%
2016-12-31 €47.92 Million
≈ $56.02 Million
-0.27%
2015-12-31 €48.05 Million
≈ $56.18 Million
+177.89%
2014-12-31 €17.29 Million
≈ $20.22 Million
+11.65%
2013-12-31 €15.49 Million
≈ $18.11 Million
+2.85%
2012-12-31 €15.06 Million
≈ $17.60 Million
+149.42%
2011-12-31 €6.04 Million
≈ $7.06 Million
-31.43%
2010-12-31 €8.80 Million
≈ $10.29 Million
--

About Celyad SA

BR:CYAD Belgium Biotechnology
Market Cap
$12.61 Million
€10.79 Million EUR
Market Cap Rank
#27449 Global
#105 in Belgium
Share Price
€0.24
Change (1 day)
+0.42%
52-Week Range
€0.17 - €0.50
All Time High
€54.05
About

Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding … Read more